roferon-a solution for s/c injection
f. hoffmann-la roche ltd. - interferon alfa-2a - solution for s/c injection - 3000000iu/0,5ml
betaferon 300microgram powder and solvent for solution for injection vials
bayer plc - interferon beta-1b - powder and solvent for solution for injection - 300microgram
viraferonpeg 50microgram powder and solvent for solution for injection pre-filled pen clearclick
merck sharp & dohme ltd - peginterferon alfa-2b - powder and solvent for solution for injection - 50microgram
viraferonpeg 80microgram powder and solvent for solution for injection pre-filled pen clearclick
merck sharp & dohme ltd - peginterferon alfa-2b - powder and solvent for solution for injection - 80microgram
viraferonpeg 120microgram powder and solvent for solution for injection pre-filled pen clearclick
merck sharp & dohme ltd - peginterferon alfa-2b - powder and solvent for solution for injection - 120microgram
viraferonpeg 150microgram powder and solvent for solution for injection pre-filled pen clearclick
merck sharp & dohme ltd - peginterferon alfa-2b - powder and solvent for solution for injection - 150microgram
viraferonpeg 100microgram powder and solvent for solution for injection pre-filled pen clearclick
merck sharp & dohme ltd - peginterferon alfa-2b - powder and solvent for solution for injection - 100microgram
betaferon injection
bayer co. (malaysia) sdn. bhd. - interferon beta-1b -
sylatron- peginterferon alfa-2b kit
merck sharp & dohme corp. - peginterferon alfa-2b (unii: g8rgg88b68) (peginterferon alfa-2b - unii:g8rgg88b68) - peginterferon alfa-2b 40 ug in 0.1 ml - sylatron™ is an alpha interferon indicated for the adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy. sylatron is contraindicated in patients with: - a history of anaphylaxis to peginterferon alfa-2b or interferon alfa-2b - autoimmune hepatitis - hepatic decompensation (child-pugh score >6 [class b and c]) risk summary based on findings from animal studies, sylatron can cause embryo-fetal harm when administered to a pregnant woman. available human data with sylatron use in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. administration of nonpegylated interferon alfa-2b was abortifacient in rhesus monkeys at doses approximately 13 times higher than the recommended dose of 6 mcg/kg/week (see data ). in the u.s. general population, the estimated background risk of major birth defects and miscarriage is 2-4% and
roferon a 4.5miu/0.5 %v/v solution for injection
roche products limited - interferon alfa-2a - solution for injection - 4.5miu/0.5 %v/v